Recently, the characterization of human and mouse CRC lesions by scRNA-Seq has identified distinct myeloid populations associated with a differential sensitivity to CSF1R blockade and responsiveness to anti-CD40 treatment [159]. The gene discussed is CD40; the disease is colorectal carcinoma.